Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.

ABSTRACT:

Background

Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen (HBsAg) and are undergoing chemotherapy.

Purpose

To determine whether preventive lamivudine reduces chemotherapy-induced hepatitis B virus (HBV)-related morbidity and mortality in patients with cancer who test positive for HBsAg.

Data sources

MEDLINE, Ovid MEDLINE, TOXNET, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched in all languages until June 2007.

Study selection

Clinical trials and cohort studies that reported the efficacy of preventive lamivudine versus control on HBV reactivation in patients who tested positive for HBsAg and were receiving chemotherapy wer

SUBMITTER: Loomba R 

PROVIDER: S-EPMC2729097 | biostudies-literature | 2008 Apr

REPOSITORIES: biostudies-literature